<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172884</url>
  </required_header>
  <id_info>
    <org_study_id>18041</org_study_id>
    <secondary_id>2016-004561-51</secondary_id>
    <nct_id>NCT03172884</nct_id>
  </id_info>
  <brief_title>Study of Copanlisib in Hepatic or Renal Impairment</brief_title>
  <official_title>An Open-label Non-randomized, Phase 1 Single Dose Study to Evaluate the Pharmacokinetics and Safety of Copanlisib in Subjects With Impaired Hepatic or Renal Function in Comparison to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics and safety of copanlisib in subjects with impaired hepatic&#xD;
      or renal function in comparison to healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2017</start_date>
  <completion_date type="Actual">May 15, 2020</completion_date>
  <primary_completion_date type="Actual">March 13, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Copanlisib in Plasma.</measure>
    <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
    <description>Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration vs. Time Curve From Zero to Infinity (AUC) of Copanlisib in Plasma.</measure>
    <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
    <description>AUC refers to area under the concentration vs time curve from 0 to infinity which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h.</measure>
    <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
    <description>AUC(0-168) refers to AUC from time 0 to 168 hr which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Metabolite M-1.</measure>
    <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
    <description>The morpholinone derivative M-1 is a minor copanlisib metabolite in plasma. The PK of metabolite M-1 is routinely analyzed in addition to the PK of the parent compound, although M-1 is not considered to be a major metabolite. Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve of Metabolite M-1 in Plasma Over the Time Interval From 0 to 168 h.</measure>
    <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
    <description>The morpholinone derivative M-1 is a minor copanlisib metabolite in plasma. The PK of metabolite M-1 is routinely analyzed in addition to the PK of the parent compound, although M-1 is not considered to be a major metabolite. AUC from time 0 to 168h which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to 30 days after end of treatment with study drug</time_frame>
    <description>Adverse events are considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent Adverse Events (TEAEs) in Different Severity.</measure>
    <time_frame>Up to 30 days after end of treatment with study drug</time_frame>
    <description>Adverse events are considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hepatic Insufficiency, Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>BAY80-6946/Healthy subject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY80-6946/moderate hepatically impaired patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Child-Pugh B (score 7-9) at the screening visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY80-6946/severe renal impaired patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAY80-6946/severe hepatically impaired patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Child-Pugh C (score 10-15) at the screening visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib (ALIQOPA, BAY80-6946)</intervention_name>
    <description>12mg single dose, intravenous on Day 0</description>
    <arm_group_label>BAY80-6946/Healthy subject</arm_group_label>
    <arm_group_label>BAY80-6946/moderate hepatically impaired patients</arm_group_label>
    <arm_group_label>BAY80-6946/severe hepatically impaired patients</arm_group_label>
    <arm_group_label>BAY80-6946/severe renal impaired patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All subjects - Male and female subjects between 18 and 80 years of age with a body mass&#xD;
        index above 18.0 and below 34.0 kg / m² and a body weight of above or equal 50 kg.&#xD;
&#xD;
        Healthy subjects&#xD;
&#xD;
        - Healthy subjects as determined by absence of clinically significant deviation from normal&#xD;
        in medical history, physical examination, vital signs, electrocardiograms, and clinical&#xD;
        laboratory determinations. eGFR ≥ 90 mL/min/1.73 m² (according to Modification of Diet in&#xD;
        Renal Disease [MDRD] formula).&#xD;
&#xD;
        Subjects with moderate or severe hepatic impairment&#xD;
&#xD;
          -  Subjects with confirmed liver cirrhosis by at least one of the following Criteria:&#xD;
             histologically by prior liver biopsy showing cirrhosis, liver imaging (computer&#xD;
             tomography, and/or ultrasound and/or magnetic resonance imaging scans, and/or&#xD;
             fibroscan), or laparoscopy.&#xD;
&#xD;
          -  Child-Pugh Clinical Assessment Score 7 to 9 (moderate) or Score 10 to 15 (severe).&#xD;
&#xD;
        Subjects with severe renal impairment&#xD;
&#xD;
          -  Subjects with severe renal impairment with an estimated glomerular filtration rate&#xD;
             15-29 mL/min/1.73 m² according to MDRD formula.&#xD;
&#xD;
          -  Subjects with stable renal disease: no significant change in renal function as&#xD;
             evidenced by serum creatinine value within ±25% from the last determination, obtained&#xD;
             within at least 3 months before study entry and the absence of the need to start&#xD;
             dialysis in the next 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All subjects&#xD;
&#xD;
          -  Active coronary artery disease or myocardial infarction within 6 months of study&#xD;
             entry. Immuno-compromised subjects including known history/seropositivity of human&#xD;
             immunodeficiency virus (HIV).&#xD;
&#xD;
          -  Other concurrent severe and/or uncontrolled medical conditions (e.g. current diagnosis&#xD;
             of type 1 or type 2 diabetes mellitus and with HbA1c &gt;8.5%) that could cause&#xD;
             unacceptable safety risks or compromise compliance with protocol.&#xD;
&#xD;
          -  Previous or concurrent history of malignancies within 5 years prior to study treatment&#xD;
             except for curatively treated cervical cancer in situ, non-melanoma skin cancer,&#xD;
             superficial bladder cancer as well as localized prostate cancer.&#xD;
&#xD;
          -  Uncontrolled hypertension despite optimal medical management (per investigator's&#xD;
             assessment).&#xD;
&#xD;
          -  Administration of strong CYP3A4 inhibitors or inducers within 2 weeks prior to dosing&#xD;
             and during study conduct. (A list of these medications can be found in Section 16.6 of&#xD;
             the protocol. However, this list may not be comprehensive).&#xD;
&#xD;
        Subjects with moderate or severe hepatic impairment&#xD;
&#xD;
          -  Symptoms or history of encephalopathy (Grade III or worse)&#xD;
&#xD;
          -  Failure of any other major organ other than the liver; severe infection, or any&#xD;
             clinically significant illness within 4 weeks prior to study drug administration&#xD;
&#xD;
          -  Renal failure with an eGFR &lt;35 mL/min/1.73 m² Subjects with severe renal impairment&#xD;
&#xD;
          -  Acute renal failure at study entry&#xD;
&#xD;
          -  Nephrotic syndrome&#xD;
&#xD;
          -  Failure of any other major organ other than the kidney&#xD;
&#xD;
          -  Acute hepatorenal syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical-Research-Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institutul National de Boli Infectioase Prof.Dr.Matei Bals</name>
      <address>
        <city>Bucuresti</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Romania</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <link>
    <url>http://clinicaltrials.bayer.com/</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <results_first_submitted>March 10, 2021</results_first_submitted>
  <results_first_submitted_qc>March 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 1, 2021</results_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Impairment</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Hepatic impairment</keyword>
  <keyword>Envisaged indication: Treatment of cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, time point and process of data access. As such, Bayer commits to sharing upon request from qualified researcher's patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03172884/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03172884/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted in Germany and Romania between 14 Jun 2017 (first patient's first visit) and 13 Mar 2020 (last patient's last visit).</recruitment_details>
      <pre_assignment_details>50 participants were screened in study. 16 were screen failure and 4 withdrew from study. 30 participants were assigned to study arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Moderate Hepatic Impairment Group</title>
          <description>Child-Pugh B (score 7-9) at the screening visit</description>
        </group>
        <group group_id="P2">
          <title>Severe Hepatic Impairment Group</title>
          <description>Child-Pugh C (score 10-15) at the screening visit</description>
        </group>
        <group group_id="P3">
          <title>Severe Renal Impairment Group</title>
          <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
        </group>
        <group group_id="P4">
          <title>Healthy Participants</title>
          <description>Normal hepatic and renal function group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Moderate Hepatic Impairment Group</title>
          <description>Child-Pugh B (score 7-9) at the screening visit</description>
        </group>
        <group group_id="B2">
          <title>Severe Hepatic Impairment Group</title>
          <description>Child-Pugh C (score 10-15) at the screening visit</description>
        </group>
        <group group_id="B3">
          <title>Severe Renal Impairment Group</title>
          <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
        </group>
        <group group_id="B4">
          <title>Healthy Participants</title>
          <description>Normal hepatic and renal function group</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" spread="9.4"/>
                    <measurement group_id="B2" value="47.5" spread="11.1"/>
                    <measurement group_id="B3" value="65.8" spread="12.1"/>
                    <measurement group_id="B4" value="60.9" spread="6.6"/>
                    <measurement group_id="B5" value="60.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>In utero</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preterm newborn infants (gestational age &lt; 37 wks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Newborns (0-27 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infants and toddlers (28 days-23 months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Children (2-11 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adolescents (12-17 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adults (18-64 years)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>From 65-84 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>85 years and over</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body mass index: weight [kg] / (height [m])²</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.90" spread="4.68"/>
                    <measurement group_id="B2" value="27.12" spread="4.76"/>
                    <measurement group_id="B3" value="26.60" spread="3.07"/>
                    <measurement group_id="B4" value="26.48" spread="1.64"/>
                    <measurement group_id="B5" value="27.02" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of Copanlisib in Plasma.</title>
        <description>Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
        <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Child-Pugh B (score 7-9) at the screening visit</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment Group</title>
            <description>Child-Pugh C (score 10-15) at the screening visit</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment Group</title>
            <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
          </group>
          <group group_id="O4">
            <title>Healthy Participants</title>
            <description>Normal hepatic and renal function group</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Copanlisib in Plasma.</title>
          <description>Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
          <units>μg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.12" spread="65.50" lower_limit="65.50"/>
                    <measurement group_id="O2" value="71.09" spread="53.90" lower_limit="53.90"/>
                    <measurement group_id="O3" value="31.77" spread="38.25" lower_limit="38.25"/>
                    <measurement group_id="O4" value="49.20" spread="27.24" lower_limit="27.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moderate Hepatic Impairment vs Healthy Subjects</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means</param_type>
            <param_value>1.385</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.921</ci_lower_limit>
            <ci_upper_limit>2.081</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe hepatic impairment group vs Healthy Subjects</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means</param_type>
            <param_value>1.445</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.998</ci_lower_limit>
            <ci_upper_limit>2.093</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe renal impairment group vs Healthy Subjects</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS means</param_type>
            <param_value>0.646</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.486</ci_lower_limit>
            <ci_upper_limit>0.858</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration vs. Time Curve From Zero to Infinity (AUC) of Copanlisib in Plasma.</title>
        <description>AUC refers to area under the concentration vs time curve from 0 to infinity which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
        <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
        <population>Participants in PK population with available data are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Child-Pugh B (score 7-9) at the screening visit</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment Group</title>
            <description>Child-Pugh C (score 10-15) at the screening visit</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment Group</title>
            <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
          </group>
          <group group_id="O4">
            <title>Healthy Participants</title>
            <description>Normal hepatic and renal function group</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration vs. Time Curve From Zero to Infinity (AUC) of Copanlisib in Plasma.</title>
          <description>AUC refers to area under the concentration vs time curve from 0 to infinity which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
          <population>Participants in PK population with available data are reported.</population>
          <units>μg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="594.9" spread="53.85"/>
                    <measurement group_id="O2" value="940.7" spread="23.70"/>
                    <measurement group_id="O3" value="373.7" spread="59.08"/>
                    <measurement group_id="O4" value="347.8" spread="23.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moderate Hepatic Impairment group vs Healthy Subjects</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Means</param_type>
            <param_value>1.711</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.148</ci_lower_limit>
            <ci_upper_limit>2.550</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe hepatic impairment group vs Healthy Subjects</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Means</param_type>
            <param_value>2.705</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.115</ci_lower_limit>
            <ci_upper_limit>3.460</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe renal impairment group vs Healthy Subjects</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Means</param_type>
            <param_value>1.075</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.696</ci_lower_limit>
            <ci_upper_limit>1.659</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h.</title>
        <description>AUC(0-168) refers to AUC from time 0 to 168 hr which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
        <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Child-Pugh B (score 7-9) at the screening visit</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment Group</title>
            <description>Child-Pugh C (score 10-15) at the screening visit</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment Group</title>
            <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
          </group>
          <group group_id="O4">
            <title>Healthy Participants</title>
            <description>Normal hepatic and renal function group</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Copanlisib in Plasma Over the Time Interval From 0 to 168 h.</title>
          <description>AUC(0-168) refers to AUC from time 0 to 168 hr which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
          <units>μg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="551.4" spread="53.78"/>
                    <measurement group_id="O2" value="853.0" spread="26.39"/>
                    <measurement group_id="O3" value="350.5" spread="48.55"/>
                    <measurement group_id="O4" value="311.9" spread="23.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Moderate Hepatic Impairment group vs Healthy Subjects</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Means</param_type>
            <param_value>1.768</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.251</ci_lower_limit>
            <ci_upper_limit>2.498</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe hepatic impairment group vs Healthy Subjects</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Means</param_type>
            <param_value>2.735</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.163</ci_lower_limit>
            <ci_upper_limit>3.459</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Severe renal impairment group vs Healthy Subjects</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>LS Means</param_type>
            <param_value>1.124</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.815</ci_lower_limit>
            <ci_upper_limit>1.549</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of Metabolite M-1.</title>
        <description>The morpholinone derivative M-1 is a minor copanlisib metabolite in plasma. The PK of metabolite M-1 is routinely analyzed in addition to the PK of the parent compound, although M-1 is not considered to be a major metabolite. Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
        <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
        <population>Participants in PK population with available data are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Child-Pugh B (score 7-9) at the screening visit</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment Group</title>
            <description>Child-Pugh C (score 10-15) at the screening visit</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment Group</title>
            <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
          </group>
          <group group_id="O4">
            <title>Healthy Participants</title>
            <description>Normal hepatic and renal function group</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Metabolite M-1.</title>
          <description>The morpholinone derivative M-1 is a minor copanlisib metabolite in plasma. The PK of metabolite M-1 is routinely analyzed in addition to the PK of the parent compound, although M-1 is not considered to be a major metabolite. Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
          <population>Participants in PK population with available data are reported.</population>
          <units>μg/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.868" spread="53.16"/>
                    <measurement group_id="O2" value="1.356" spread="52.63"/>
                    <measurement group_id="O3" value="1.440" spread="50.36"/>
                    <measurement group_id="O4" value="1.543" spread="47.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve of Metabolite M-1 in Plasma Over the Time Interval From 0 to 168 h.</title>
        <description>The morpholinone derivative M-1 is a minor copanlisib metabolite in plasma. The PK of metabolite M-1 is routinely analyzed in addition to the PK of the parent compound, although M-1 is not considered to be a major metabolite. AUC from time 0 to 168h which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
        <time_frame>before copanlisib administration as well as 10 min and 1 h (end of infusion), 1.5, 2, 2.5, 3, 5, 8, 24, 48, 72, 96, 120 and 168 h after start of infusion</time_frame>
        <population>Participants in PK population with available data are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Child-Pugh B (score 7-9) at the screening visit</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment Group</title>
            <description>Child-Pugh C (score 10-15) at the screening visit</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment Group</title>
            <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
          </group>
          <group group_id="O4">
            <title>Healthy Participants</title>
            <description>Normal hepatic and renal function group</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Metabolite M-1 in Plasma Over the Time Interval From 0 to 168 h.</title>
          <description>The morpholinone derivative M-1 is a minor copanlisib metabolite in plasma. The PK of metabolite M-1 is routinely analyzed in addition to the PK of the parent compound, although M-1 is not considered to be a major metabolite. AUC from time 0 to 168h which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.</description>
          <population>Participants in PK population with available data are reported.</population>
          <units>μg*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.62" spread="59.06" lower_limit="59.06"/>
                    <measurement group_id="O2" value="83.00" spread="35.34" lower_limit="35.34"/>
                    <measurement group_id="O3" value="67.12" spread="70.48" lower_limit="70.48"/>
                    <measurement group_id="O4" value="74.68" spread="76.75" lower_limit="76.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Adverse events are considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.</description>
        <time_frame>Up to 30 days after end of treatment with study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Child-Pugh B (score 7-9) at the screening visit</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment Group</title>
            <description>Child-Pugh C (score 10-15) at the screening visit</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment Group</title>
            <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
          </group>
          <group group_id="O4">
            <title>Healthy Participants</title>
            <description>Normal hepatic and renal function group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Adverse events are considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Adverse events (AE's)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Serious adverse events (SAE's)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent Adverse Events (TEAEs) in Different Severity.</title>
        <description>Adverse events are considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.</description>
        <time_frame>Up to 30 days after end of treatment with study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment Group</title>
            <description>Child-Pugh B (score 7-9) at the screening visit</description>
          </group>
          <group group_id="O2">
            <title>Severe Hepatic Impairment Group</title>
            <description>Child-Pugh C (score 10-15) at the screening visit</description>
          </group>
          <group group_id="O3">
            <title>Severe Renal Impairment Group</title>
            <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
          </group>
          <group group_id="O4">
            <title>Healthy Participants</title>
            <description>Normal hepatic and renal function group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent Adverse Events (TEAEs) in Different Severity.</title>
          <description>Adverse events are considered to be treatment-emergent if they have started or worsened after first application of study medication up to 30 days after end of treatment with study medication.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first administration of study drug up to 30 days after end of treatment with study medication.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Moderate Hepatic Impairment Group</title>
          <description>Subjects with Child-Pugh B (score 7-9) at the screening visit.</description>
        </group>
        <group group_id="E2">
          <title>Severe Hepatic Impairment Group</title>
          <description>Child-Pugh C (score 10-15) at the screening visit</description>
        </group>
        <group group_id="E3">
          <title>Severe Renal Impairment Group</title>
          <description>eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation</description>
        </group>
        <group group_id="E4">
          <title>Healthy Participants</title>
          <description>Normal hepatic and renal function group</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Center will refrain from making any publications and shall not publish any press releases or other public announcements or statements about this Agreement, the Study, the Results of the Study and/or the Study Drug without Bayer's prior written consent.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Bayer AG</organization>
      <phone>(+) 1-888-8422937</phone>
      <email>clinical-trials-contact@bayer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

